Trial · NCT06971900
GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria
NCT06971900, Phase 2, Completed, Portal Therapeutics, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria. Trials, record NCT06971900. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06971900
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria
- NCT number
- NCT06971900
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 28 participants, actual
- Lead sponsor
- Portal Therapeutics, Inc.
- Conditions
- Erythropoietic Protoporphyria (EPP)
- Interventions
- PORT-77, Placebo
- First posted
- 2025-05-14
- Last updated
- 2026-07-29
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Plasma PPIX level | 9 Days | Change over the course of the study in plasma PPIX concentrations |
| Secondary | Safety and tolerability | 9 Days | Evaluate safety and tolerability of PORT-77 over the course of the study |
| Secondary | Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-last) | Day 1 through Day 9 | Area under the plasma concentration-time curve from time zero to the last measurable concentration of PORT-77 |
| Secondary | Area Under the Plasma Concentration-Time Curve Over the 12-Hour Dosing Interval at Steady State (AUC0-12) | Up to Day 8 | Area under the plasma concentration-time curve over the 12-hour dosing interval at steady state. |
| Secondary | Area Under the Plasma Concentration-Time Curve Over the 24-Hour Dosing Interval at Steady State (AUC0-24) | Up to Day 8 | Area under the plasma concentration-time curve over the 24-hour dosing interval at steady state. |
| Secondary | Maximum Observed Plasma Concentration (Cmax) | Day 1 through Day 9 | Maximum observed plasma concentration of PORT-77 |
| Secondary | Trough Plasma Concentration (Ctrough) | Up to Day 8 | Observed plasma concentration at the end of the dosing interval. |
| Secondary | Time to Maximum Observed Plasma Concentration (Tmax) | Day 1 through Day 9 | Time after dosing at which maximum observed plasma concentration is reached. |
| Secondary | Time of Last Quantifiable Plasma Concentration (Tlast) | Day 1 through Day 9 | Time corresponding to the last measurable plasma concentration. |
| Secondary | Terminal Elimination Half-Life (t½) | Day 1 through Day 9 | Apparent first-order terminal elimination half-life. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06971900
GET https://conductscience.org/api/trials/v1/NCT06971900/registered